MedTrace Logo

CD155 Expression in Acute Myeloid Leukemia

NCT06369662 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2024-10-16

No results posted yet for this study

Summary

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020.

CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival.

Conditions

  • Neoplasms
  • Hematologic Neoplasms
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute

Interventions

DIAGNOSTIC_TEST

Flow cytometric immunophenotyping

CD155 expression by flow cytometric immunophenotyping

DIAGNOSTIC_TEST

Complete blood count

Complete blood count with peripheral blood smear examination

DIAGNOSTIC_TEST

Bone marrow aspiration

Bone marrow aspiration at both diagnosis and follow up of patients

DIAGNOSTIC_TEST

Cytogenetic testing

Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients

DIAGNOSTIC_TEST

FLT3-ITD using High resolution melting curve (HRM) analysis

Detection of FLT3-ITD mutation in AML patinets

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Nehal Rayan, M.D. · Assistant Lecturer

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2024-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06369662 on ClinicalTrials.gov